These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19496334)

  • 41. Methoxy poly(ethylene glycol) and epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours.
    Kim SY; Shin IG; Lee YM; Cho CS; Sung YK
    J Control Release; 1998 Jan; 51(1):13-22. PubMed ID: 9685900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design of multicomponent indomethacin-paracetamol and famotidine loaded nanoparticles for sustained and effective anti-inflammatory therapy.
    Assali M; Zohud N
    Drug Dev Res; 2021 May; 82(3):448-457. PubMed ID: 33263203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of photostability and photodegradation products of indomethacin in aqueous media.
    Temussi F; Cermola F; Dellagreca M; Iesce MR; Passananti M; Previtera L; Zarrelli A
    J Pharm Biomed Anal; 2011 Dec; 56(4):678-83. PubMed ID: 21807472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Local delivery of indomethacin to arthritis-bearing rats through polymeric micelles based on amphiphilic polyphosphazenes.
    Zhang JX; Yan MQ; Li XH; Qiu LY; Li XD; Li XJ; Jin Y; Zhu KJ
    Pharm Res; 2007 Oct; 24(10):1944-53. PubMed ID: 17530389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel nanostructured supramolecular hydrogels for the topical delivery of anionic drugs.
    Limón D; Amirthalingam E; Rodrigues M; Halbaut L; Andrade B; Garduño-Ramírez ML; Amabilino DB; Pérez-García L; Calpena AC
    Eur J Pharm Biopharm; 2015 Oct; 96():421-36. PubMed ID: 26409201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethacin [correction of indomethicin].
    Pan X; Julian T; Augsburger L
    Drug Dev Ind Pharm; 2008 Feb; 34(2):221-31. PubMed ID: 18302042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterising surface energy of pharmaceutical powders by inverse gas chromatography at finite dilution.
    Das SC; Stewart PJ
    J Pharm Pharmacol; 2012 Sep; 64(9):1337-48. PubMed ID: 22881445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Controlled release of indomethacin from alginate-poloxamer-silicon carbide composites decrease in-vitro inflammation.
    Díaz-Rodríguez P; Landin M
    Int J Pharm; 2015 Mar; 480(1-2):92-100. PubMed ID: 25596416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization of formulation variables affecting spray-dried oily core nanocapsules by response surface methodology.
    Zhang T; Murowchick J; Youan BB
    J Pharm Sci; 2011 Mar; 100(3):1031-44. PubMed ID: 20928871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility of the Ph.Eur. flow-through cell for dissolution testing of the compounded rectal suppositories containing indomethacin or sodium diclofenac.
    Woyczikowski B; Szulc J; Sznitowska M; Janicki S; Pilichowski J; Urbańska A
    Acta Pol Pharm; 2003; 60(3):169-72. PubMed ID: 14556483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancement of water solubility of indomethacin by complexation with protein hydrolysate.
    Inada A; Oshima T; Takahashi H; Baba Y
    Int J Pharm; 2013 Sep; 453(2):587-93. PubMed ID: 23742973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
    Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
    Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.
    Balguri SP; Adelli GR; Majumdar S
    Eur J Pharm Biopharm; 2016 Dec; 109():224-235. PubMed ID: 27793755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors Affecting the Dissolution of Indomethacin Solid Dispersions.
    Zhang W; Zhang CN; He Y; Duan BY; Yang GY; Ma WD; Zhang YH
    AAPS PharmSciTech; 2017 Nov; 18(8):3258-3273. PubMed ID: 28584898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulation of indomethacin eye drops via complexation with cyclodextrins.
    Halim Mohamed MA; Mahmoud AA
    Curr Eye Res; 2011 Mar; 36(3):208-16. PubMed ID: 21275515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beads made of α-cyclodextrin and soybean oil: the drying method influences bead properties and drug release.
    Hamoudi MC; Saunier J; Gueutin C; Fattal E; Bochot A
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1306-14. PubMed ID: 23050693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of indomethacin Carbopol ETD 2001 gels and the influence of storage time and temperature on their stability.
    Shawesh AM; Kaukonen A; Kallioinen S; Antikainen O; Yliruusi J
    Pharmazie; 2003 Feb; 58(2):130-5. PubMed ID: 12641331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel, dynamic on-line analytical separation system for dissolution of drugs from poly(lactic acid) nanoparticles.
    Helle A; Hirsjärvi S; Peltonen L; Hirvonen J; Wiedmer SK; Hyötyläinen T
    J Pharm Biomed Anal; 2010 Jan; 51(1):125-30. PubMed ID: 19744811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability.
    Nagai N; Ito Y; Okamoto N; Shimomura Y
    Toxicology; 2014 May; 319():53-62. PubMed ID: 24598350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rate-modulating PHBHV/PCL microparticles containing weak acid model drugs.
    Poletto FS; Jäger E; Ré MI; Guterres SS; Pohlmann AR
    Int J Pharm; 2007 Dec; 345(1-2):70-80. PubMed ID: 17604922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.